Switch to:
Also traded in: France, Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.56
SNY's Cash-to-Debt is ranked lower than
67% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. SNY: 0.56 )
Ranked among companies with meaningful Cash-to-Debt only.
SNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.56 Max: 10.62
Current: 0.56
0.14
10.62
Equity-to-Asset 0.55
SNY's Equity-to-Asset is ranked lower than
62% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. SNY: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
SNY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.58 Max: 0.65
Current: 0.55
0.48
0.65
Interest Coverage 23.85
SNY's Interest Coverage is ranked lower than
63% of the 638 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.48 vs. SNY: 23.85 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s Interest Coverage Range Over the Past 10 Years
Min: 7.88  Med: 15.48 Max: 23.85
Current: 23.85
7.88
23.85
Piotroski F-Score: 7
Altman Z-Score: 2.08
Beneish M-Score: -2.64
WACC vs ROIC
6.04%
7.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 18.83
SNY's Operating Margin % is ranked higher than
79% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. SNY: 18.83 )
Ranked among companies with meaningful Operating Margin % only.
SNY' s Operating Margin % Range Over the Past 10 Years
Min: 15.25  Med: 18.36 Max: 20.7
Current: 18.83
15.25
20.7
Net Margin % 13.57
SNY's Net Margin % is ranked higher than
74% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. SNY: 13.57 )
Ranked among companies with meaningful Net Margin % only.
SNY' s Net Margin % Range Over the Past 10 Years
Min: 11.88  Med: 13.66 Max: 18.02
Current: 13.57
11.88
18.02
ROE % 8.32
SNY's ROE % is ranked higher than
54% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. SNY: 8.32 )
Ranked among companies with meaningful ROE % only.
SNY' s ROE % Range Over the Past 10 Years
Min: 6.5  Med: 8.61 Max: 11.68
Current: 8.32
6.5
11.68
ROA % 4.62
SNY's ROA % is ranked higher than
56% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. SNY: 4.62 )
Ranked among companies with meaningful ROA % only.
SNY' s ROA % Range Over the Past 10 Years
Min: 3.78  Med: 5.11 Max: 7.03
Current: 4.62
3.78
7.03
ROC (Joel Greenblatt) % 48.18
SNY's ROC (Joel Greenblatt) % is ranked higher than
82% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.07 vs. SNY: 48.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 31.14  Med: 42.95 Max: 63.82
Current: 48.18
31.14
63.82
3-Year Revenue Growth Rate 4.70
SNY's 3-Year Revenue Growth Rate is ranked lower than
52% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. SNY: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.5  Med: 6.3 Max: 27.4
Current: 4.7
-3.5
27.4
3-Year EBITDA Growth Rate -2.10
SNY's 3-Year EBITDA Growth Rate is ranked lower than
69% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. SNY: -2.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 4.2 Max: 35.5
Current: -2.1
-7.1
35.5
3-Year EPS without NRI Growth Rate 7.70
SNY's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 580 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. SNY: 7.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -13.4  Med: 3.4 Max: 41.7
Current: 7.7
-13.4
41.7
GuruFocus has detected 5 Warning Signs with Sanofi SA $SNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SNY's 30-Y Financials

Financials (Next Earnings Date: 2017-10-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:ABBV, OTCPK:BAYZF, OTCPK:GLAXF, NYSE:BMY, NYSE:LLY, NYSE:AZN, NYSE:MRK, OTCPK:NVSEF, NYSE:PFE, OTCPK:SZUKF, OTCPK:RHHBY, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, OTCPK:OPHLY, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHF, NAS:HCM » details
Traded in other countries:SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Headquarter Location:France
Sanofi SA is a healthcare company engaged in the research, development, manufacture and marketing of healthcare products.

Sanofi develops and markets drugs with a concentration in oncology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing close to 15% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales.

Guru Investment Theses on Sanofi SA

First Eagle Investments Comments on Sanofi - Oct 24, 2016

Sanofi (NYSE:SNY) is a French pharmaceutical company that experienced softness in its diabetes business in the United States. The company’s US patent for Lantus, its primary insulin drug, expired in 2015, and competition from less expensive biosimilars weighted on Sano-fi’s share price. At the same time, Sanofi’s vaccines business and the specialty care areas its acquired in the purchase of Genzyme did well during the quarter.



From First Eagle Global Value Fund third-quarter 2016 commentary.



Check out First Eagle Investment latest stock trades

Top Ranked Articles about Sanofi SA

Good Companies From Warren Buffett’s Portfolio Strong profit margins lead to investing opportunities
Four companies from Warren Buffett (Trades, Portfolio)’s current portfolio offer good growth and value potential for the second half of the year: Proctor & Gamble Co. (NYSE:PG), Sirius XM Holdings Inc. (NASDAQ:SIRI), Sanofi SA (NYSE:SNY) and VeriSign Inc. (NASDAQ:VRSN). Read more...
Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
New Analysis Shows Sanofi's Soliqua® 100/33 Lowered HbA1c by More Than 2 Percent in Patients with Screening Levels Greater than 9 Percent
Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
Bill Nygren Gains 3 Holdings, Divests 2 Others in 1st Quarter Guru releases quarterly portfolio
Oakmark Funds’ Bill Nygren (Trades, Portfolio) established three positions and sold two others during the first quarter. Read more...
Buffett Deploys Cash in Deutschland Berkshire Hathaway buys stake in Lanxess
Warren Buffett (Trades, Portfolio)’s Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) disclosed a stake in Germany’s Lanxess AG (FRA:LXS) on May 19, worth roughly $179.85 million on the date of filing, a small fraction of his $96.5 billion cash hoard. Read more...
Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients

Ratios

vs
industry
vs
history
PE Ratio 24.21
SNY's PE Ratio is ranked higher than
57% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.96 vs. SNY: 24.21 )
Ranked among companies with meaningful PE Ratio only.
SNY' s PE Ratio Range Over the Past 10 Years
Min: 9.75  Med: 19.91 Max: 32.04
Current: 24.21
9.75
32.04
Forward PE Ratio 15.67
SNY's Forward PE Ratio is ranked higher than
71% of the 68 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.46 vs. SNY: 15.67 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 25.89
SNY's PE Ratio without NRI is ranked higher than
53% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.64 vs. SNY: 25.89 )
Ranked among companies with meaningful PE Ratio without NRI only.
SNY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.04  Med: 19.91 Max: 32.67
Current: 25.89
10.04
32.67
Price-to-Owner-Earnings 16.96
SNY's Price-to-Owner-Earnings is ranked higher than
77% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. SNY: 16.96 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SNY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.31  Med: 13.31 Max: 21.33
Current: 16.96
7.31
21.33
PB Ratio 1.97
SNY's PB Ratio is ranked higher than
66% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. SNY: 1.97 )
Ranked among companies with meaningful PB Ratio only.
SNY' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 1.64 Max: 2.33
Current: 1.97
1.16
2.33
PS Ratio 3.24
SNY's PS Ratio is ranked lower than
53% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. SNY: 3.24 )
Ranked among companies with meaningful PS Ratio only.
SNY' s PS Ratio Range Over the Past 10 Years
Min: 1.76  Med: 2.67 Max: 4.12
Current: 3.24
1.76
4.12
Price-to-Free-Cash-Flow 18.65
SNY's Price-to-Free-Cash-Flow is ranked higher than
63% of the 209 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.35 vs. SNY: 18.65 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SNY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.49  Med: 14.86 Max: 21.14
Current: 18.65
7.49
21.14
Price-to-Operating-Cash-Flow 13.92
SNY's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.13 vs. SNY: 13.92 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SNY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.08  Med: 10.59 Max: 17.15
Current: 13.92
6.08
17.15
EV-to-EBIT 20.46
SNY's EV-to-EBIT is ranked higher than
50% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.48 vs. SNY: 20.46 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.1  Med: 16.6 Max: 24.6
Current: 20.46
9.1
24.6
EV-to-EBITDA 13.13
SNY's EV-to-EBITDA is ranked higher than
65% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.55 vs. SNY: 13.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 8.55 Max: 15
Current: 13.13
5.1
15
Shiller PE Ratio 22.83
SNY's Shiller PE Ratio is ranked higher than
77% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.91 vs. SNY: 22.83 )
Ranked among companies with meaningful Shiller PE Ratio only.
SNY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.64  Med: 19.95 Max: 27.21
Current: 22.83
14.64
27.21
Current Ratio 1.62
SNY's Current Ratio is ranked lower than
68% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. SNY: 1.62 )
Ranked among companies with meaningful Current Ratio only.
SNY' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.65 Max: 2.71
Current: 1.62
0.79
2.71
Quick Ratio 1.20
SNY's Quick Ratio is ranked lower than
68% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. SNY: 1.20 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.23 Max: 2.41
Current: 1.2
0.59
2.41
Days Inventory 232.77
SNY's Days Inventory is ranked lower than
87% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. SNY: 232.77 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 178.09  Med: 195.24 Max: 232.77
Current: 232.77
178.09
232.77
Days Sales Outstanding 76.88
SNY's Days Sales Outstanding is ranked lower than
52% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. SNY: 76.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.29  Med: 76.54 Max: 83.73
Current: 76.88
61.29
83.73
Days Payable 146.55
SNY's Days Payable is ranked higher than
83% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.86 vs. SNY: 146.55 )
Ranked among companies with meaningful Days Payable only.
SNY' s Days Payable Range Over the Past 10 Years
Min: 104.92  Med: 125.26 Max: 146.55
Current: 146.55
104.92
146.55

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.35
SNY's Dividend Yield % is ranked higher than
86% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. SNY: 3.35 )
Ranked among companies with meaningful Dividend Yield % only.
SNY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.46  Med: 3.75 Max: 5.24
Current: 3.35
2.46
5.24
Dividend Payout Ratio 0.86
SNY's Dividend Payout Ratio is ranked lower than
88% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. SNY: 0.86 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SNY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.72 Max: 1.02
Current: 0.86
0.46
1.02
3-Year Dividend Growth Rate 1.90
SNY's 3-Year Dividend Growth Rate is ranked lower than
64% of the 302 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. SNY: 1.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SNY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -15.6  Med: 7.8 Max: 37.9
Current: 1.9
-15.6
37.9
Forward Dividend Yield % 3.31
SNY's Forward Dividend Yield % is ranked higher than
82% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.71 vs. SNY: 3.31 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.88
SNY's 5-Year Yield-on-Cost % is ranked higher than
78% of the 846 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.18 vs. SNY: 3.88 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SNY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.85  Med: 4.35 Max: 6.07
Current: 3.88
2.85
6.07
3-Year Average Share Buyback Ratio 0.80
SNY's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. SNY: 0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.5  Med: -0.1 Max: 2.2
Current: 0.8
-24.5
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 17.79
SNY's Price-to-Tangible-Book is ranked lower than
92% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. SNY: 17.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.22  Med: 14.99 Max: 41.94
Current: 17.79
7.22
41.94
Price-to-Intrinsic-Value-Projected-FCF 1.07
SNY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. SNY: 1.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SNY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.57  Med: 0.93 Max: 1.45
Current: 1.07
0.57
1.45
Price-to-Median-PS-Value 1.23
SNY's Price-to-Median-PS-Value is ranked lower than
59% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. SNY: 1.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.69  Med: 1.18 Max: 3.54
Current: 1.23
0.69
3.54
Price-to-Graham-Number 4.52
SNY's Price-to-Graham-Number is ranked lower than
84% of the 484 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. SNY: 4.52 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SNY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.92  Med: 4.07 Max: 6.63
Current: 4.52
1.92
6.63
Earnings Yield (Greenblatt) % 4.88
SNY's Earnings Yield (Greenblatt) % is ranked higher than
66% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. SNY: 4.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.1  Med: 6 Max: 11
Current: 4.88
4.1
11
Forward Rate of Return (Yacktman) % 1.27
SNY's Forward Rate of Return (Yacktman) % is ranked lower than
67% of the 381 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. SNY: 1.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SNY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.7  Med: 10.9 Max: 24
Current: 1.27
0.7
24

More Statistics

Revenue (TTM) (Mil) $37,727.93
EPS (TTM) $ 1.97
Beta0.75
Short Percentage of Float0.00%
52-Week Range $36.81 - 50.24
Shares Outstanding (Mil)2,584.04 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 41,342 43,168 45,657
EPS ($) 3.20 3.39 3.91
EPS without NRI ($) 3.20 3.39 3.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.86%
Dividends per Share ($) 1.71 1.79 1.94
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Oracle Slowly Gaining Momentum on the Cloud Front Jun 26 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 
Stocks That Fell to 3-Year Lows in the Week of June 23 Jun 24 2017 
Weekly Top Insider Buys Highlight for the Week of June 23 Jun 24 2017 
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 
Delta and Korean Air Create Leading trans-Pacific Joint Venture Jun 23 2017 

More From Other Websites
Regeneron: The More the Merrier? Jun 27 2017
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU Jun 27 2017
Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion Jun 27 2017
Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to... Jun 27 2017
Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with... Jun 27 2017
Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with... Jun 27 2017
[$$] Third Point Move Could Lead to Nestlé-L’Oréal Decoupling Jun 26 2017
Domino Effect: Nestle Sale of L'Oreal Could Trigger Sanofi Move Jun 26 2017
Good Companies From Warren Buffett's Portfolio Jun 23 2017
Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout Jun 23 2017
Vertex on the Street: Analysts’ Recommendations in June 2017 Jun 23 2017
Drugmakers May Lose $390B In Sales Over 5 Years Jun 22 2017
Shire (SHPG) Receives MAA Validation for Veyvondi by EMA Jun 22 2017
Why ImmunoGen, Inc. Jumped Higher Today Jun 20 2017
Eosinophilic Esophagitis: Major Market Opportunity for Dupixent? Jun 20 2017
Dupixent May Prove Effective in Multiple Diseases Jun 20 2017
Horizon Pharma Gets Health Canada Approval for Procysbi Jun 20 2017
Dupixent May Be a Major Growth Driver for Regeneron in 2017 Jun 20 2017
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio Jun 20 2017
Regeneron’s Praluent May See Gradual Increase in 2017 Demand Jun 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}